Clinical trial · Observational
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Real-world Experience of Anti-PD-1 Immunotherapy Plus Chemotherapy as First-line Treatment for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China(REACTION Trial).
NCT05142709CI-TRIAL-00102486completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti-PD-1 Immune Checkpoint Inhibitors | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- ESCC patients treated with anti-PD-1 immunotherapy as 1st line treatment.
- interventionNames
- Drug: Anti-PD-1 Immune Checkpoint Inhibitors
Primary outcomes (1)
- measure
- OS from start of 1st line treatment in metastatic ESCC
- timeFrame
- 2 years
- description
- Median OS and OS rate at 12 months, 18 months and 24 months will be analysed based on Kaplan-Meier method and presented along with its 95% confidence interval.
Secondary outcomes (2)
- measure
- PFS from start of 1st line treatment in metastatic ESCC
- timeFrame
- 18 months
- description
- Median PFS and PFS rate at 6 months, 12months and 18 months will be analysed based on Kaplan-Meier method and presented along with its 95% confidence interval.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Age \> 18, had an Eastern Cooperative Oncology Group performance status score of 0-3; Patients had unresectable or recurrent disease that precluded esophagectomy or definitive chemoradiation, or distant metastatic disease; Patients had received no previous systemic therapy (patients who had progressed ≥6 months after \[neo\]adjuvant therapy or definitive chemoradiation were eligible); Patients accepted at least one cycle of anti-PD-1 immunotherapy as 1st line treatment, combined chemotherapy was allowed. Patients who provided informed consent by appropriate methods. In dead case, optout will be applicable. Exclusion Criteria: Patients who are prior exposure to immune-mediated therapy.
References
Publications (1)
- DERIVEDLiu Q, Chen J, Shen W, Ye J, Luo H, Zhang X, Liu W, Xu Y, Zhang Y, Liu A, Li X, Ge H, Wang Q, Luo H, Zhao L, Xie C, Lin Q, Xie C, Wang L, Zhao K. The role of thoracic radiotherapy in the setting of immunotherapy in polymetastatic esophageal squamous cell carcinoma: a multi-center cohort study. Ther Adv Med Oncol. 2026 Feb 12;18:17588359261419635. doi: 10.1177/17588359261419635. eCollection 2026. PMID 41696558